Translate Bio, Inc. (NASDAQ:TBIO) has seen 1,654,746 shares traded in the recent trading session. The company, currently valued at $1.25 Billion, closed the recent trade at $19.81 per share which meant it gained $0.3 on the day or 1.64% during that session. The TBIO stock price is -41.8% off its 52-week high price of $28.09 and 65.67% above the 52-week low of $6.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.72 Million shares traded. The 3-month trading volume is 1.35 Million shares.
The consensus among analysts is that Translate Bio, Inc. (TBIO) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 7 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.43.
Translate Bio, Inc. (NASDAQ:TBIO) trade information
Sporting 1.26% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jun 24 when the TBIO stock price touched $28.09- or saw a rise of 29.32%. Year-to-date, Translate Bio, Inc. shares have moved 143.92%, while the 5-day performance has seen it change 22.26%. Over the past 30 days, the shares of Translate Bio, Inc. (NASDAQ:TBIO) have changed -4.17%. Short interest in the company has seen 1.85 Million shares shorted with days to cover at 1.37.
Wall Street analysts have a consensus price target for the stock at $30.29, which means that the shares’ value could jump 52.9% from current levels. The projected low price target is $18 while the price target rests at a high of $40. In that case, then, we find that the current price level is +101.92% off the targeted high while a plunge would see the stock lose -9.14% from current levels.
Translate Bio, Inc. (TBIO) estimates and forecasts
Figures show that Translate Bio, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +128.64% over the past 6 months, with this year growth rate of -14.67%, compared to 12.4% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 24.6% and 2.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +105.8%.
5 analysts offering their estimates for the company have set an average revenue estimate of $2.34 Million for the current quarter. 5 have an estimated revenue figure of $4.13 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $7.17 Million and $1.32 Million respectively for this quarter and the next, and analysts expect sales will grow by -67.4% for the current quarter and 212.9% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest -1.7% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Translate Bio, Inc. (NASDAQ:TBIO)’s Major holders
Insiders own 18.09% of the company shares, while shares held by institutions stand at 86.33% with a share float percentage of 105.4%. Investors are also buoyed by the number of investors in a company, with Translate Bio, Inc. having a total of 118 institutions that hold shares in the company. The top two institutional holders are Baupost Group, Inc,.(The) LLC with over 17.54 Million shares worth more than $174.92 Million. As of March 30, 2020, Baupost Group, Inc,.(The) LLC held 27.89% of shares outstanding.
The other major institutional holder is FMR, LLC, with the holding of over 8.26 Million shares as of March 30, 2020. The firm’s total holdings are worth over $82.32 Million and represent 13.12% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Fidelity Select Portfolios – Biotechnology. As of March 30, 2020, the former fund manager holds about 4.74% shares in the company for having 2982471 shares of worth $29.74 Million while later fund manager owns 1.61 Million shares of worth $16.09 Million as of March 30, 2020, which makes it owner of about 2.56% of company’s outstanding stock.